Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study Meeting Abstract
| Authors: | Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N. T.; Chae, Y. S.; Lee, K. S.; Niikura, N.; Park, Y. H.; Wang, X.; Xu, B.; Gambhire, D.; Yung, L.; Meinhardt, G.; Wang, Y.; Harbeck, N.; Cameron, D. A. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-10 |
| Language: | English |
| ACCESSION: | WOS:000891791500004 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.17_suppl.LBA3 |
| Notes: | Meeting Abstract: LBA3 -- Source: Wos |
